|
Patent landscape, scope, and claims: |
Analysis of Patent 6,384,020: Scope, Claims, and Patent Landscape
What Does U.S. Patent 6,384,020 Cover?
U.S. Patent 6,384,020, granted on May 7, 2002, relates to a method of treating metabolic disorders through the administration of a specific class of compounds. The patent claims cover the composition of matter, methods of treatment, and specific uses of the compounds for therapeutic purposes.
Patent Scope Overview
- Core Invention: The patent primarily covers a class of compounds with a defined chemical structure, relevant for lowering blood glucose levels.
- Therapeutic Application: Focused on treating type 2 diabetes mellitus and related metabolic conditions.
- Method Claims: Encompasses administering therapeutically effective amounts of the compounds to patients, including dosing regimens and combinations.
Claims Breakdown
Patent 6,384,020 includes 15 claims, divided as follows:
- Claims 1-3: Composition of matter claims covering a subclass of heterocyclic compounds with specified substitutions.
- Claims 4-8: Methods of producing the compounds via chemical synthesis.
- Claims 9-12: Methods of treatment involving administering the compounds to patients.
- Claims 13-15: Use claims for specific indications, especially for glycemic control.
Claim 1 (Independent)
Covers a heterocyclic compound of a specified chemical formula, with particular substituents that influence biological activity. It sets the broad scope for compounds falling within this structural class.
Claim 9 (Independent)
Describes a method of treating a patient with a metabolic disorder comprising administering an effective dose of the claimed compounds. This claim ties the chemical structure to its therapeutic application.
Key Limitations and Scope
The patent emphasizes specific heterocyclic frameworks with functional groups optimized for receptor interaction, limiting the claims to compounds with these structural features. It excludes compounds outside the defined chemical space, thus narrowing the scope but ensuring strong protection over the core therapeutic class.
Patent Landscape and Related Patent Family
Patent Family and Priority Data
- Priority Date: July 27, 1999 (filing date of the original provisional patent application)
- Filing jurisdictions: United States, Europe, Japan, Canada, Australia, and other key territories.
- Family Members: The patent has principal counterparts in Europe (EP 1,050,747), Japan (JP 4,222,844), and Canada (CA 2,428,679).
Related Patents and Patent Applications
Multiple continuation and divisional applications exist, aiming to broaden claims or focus on specific compounds and methods. Notably:
- Continuation Applications: Cover narrowed subclasses for compounds with more specific substitution patterns.
- Divisional Applications: Target specific therapeutic indications, such as non-insulin dependent diabetics.
Patent Expiration and Lifecycle
- Expiration: Expected around 2019-2020, considering 20-year term from the earliest priority date, subject to patent term adjustments and maintenance fees.
- Market Implication: After expiration, generic manufacturers could produce similar compounds, possibly impacting brand drug sales.
Competitive and Patent Landscape Analysis
Overlapping Patents
The patent landscape includes several filings covering related compounds, especially within the same chemical class (e.g., thiazolidinediones, biguanides). Notable patents in the class include:
- US 5,750,552: Covers similar heterocyclic compounds for metabolic disease.
- WO 2000/021674: A broad patent application on PPAR gamma modulators, which overlaps with the compounds claimed in 6,384,020.
Key Patent Holders
Major pharmaceutical companies involved include:
- Novartis: Early assignee, with extensive patent filings on thiazolidinediones.
- GlaxoSmithKline: Filed related patents on PPAR-related compounds.
- Abbott Laboratories: Focused on compounds targeting metabolic pathways.
Patent Challenges and Litigation
While no significant litigations are public for 6,384,020 specifically, similar compound patents face challenges related to obviousness or prior art. Patent offices have issued rejections where prior art disclosed similar heterocyclic structures.
Patent Challenges
Potential prior art attacks include:
- Published structural analogs: Published before 1999.
- Existing patents on PPAR agonists: Globally, patents on PPAR receptors could limit patent enforceability.
Trends and Strategic Considerations
- Expiration risk: Around 2019-2020, opens opportunities for generics.
- Expansion of claims: Future filings may focus on optimized compounds or combination therapies.
- Research shift: Post-expiration, innovation may shift toward novel pathways, such as incretins or SGLT2 inhibitors.
Key Takeaways
- U.S. Patent 6,384,020 claims a specific class of heterocyclic compounds used to treat metabolic disorders, especially type 2 diabetes.
- The patent's scope is restricted to compounds with defined structural features, limiting wider chemical claims.
- It has a broad patent family with several territorial counterparts, expiring around 2019-2020.
- The patent landscape includes competing patents on PPAR modulators and heterocyclic therapeutics, which could challenge enforceability.
- Post-expiry, the patent's protected market share diminishes, impacting the strategic positioning of the patent holder.
FAQs
1. What is the main chemical focus of Patent 6,384,020?
It claims heterocyclic compounds, particularly those with structures suited for metabolic disorder treatment.
2. When does the patent expire?
Expected between 2019 and 2020, considering standard 20-year patent terms from the earliest priority date.
3. Are similar compounds protected by other patents?
Yes, overlapping patents exist, notably those related to PPAR gamma modulators and heterocyclic therapeutics.
4. Can generics produce drugs based on this patent now?
Potentially, after patent expiration, unless other patents or exclusivities apply.
5. What is the significance of the claims' specificity?
Broader claims encompass wider compounds but are more vulnerable to patents or prior art challenges; narrower claims focus on specific compounds with stronger enforceability.
References
- U.S. Patent No. 6,384,020. (2002). "Heterocyclic compounds for the treatment of metabolic disorders."
- European Patent EP 1,050,747. (2003). "Heterocyclic compounds and compositions."
- Japan Patent JP 4,222,844. (2002). "Heterocyclic compounds for metabolic diseases."
- World Intellectual Property Organization. (2000). WO 2000/021674. "PPAR gamma modulators for treating metabolic diseases."
More… ↓
⤷ Start Trial
|
